Cargando…
Administration of isoferulic acid improved the survival rate of lethal influenza virus pneumonia in mice.
BACKGROUND: Isoferulic acid (IFA) is a main active ingredient of the rhizoma of Cimicifuga beracleifolia, which is used frequently in Japanese traditional medicine as an anti-inflammatory drug. It has been revealed that IFA inhibits the production of macrophage inflammatory protein-2 (MIP-2), which...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781695/ https://www.ncbi.nlm.nih.gov/pubmed/11405556 |
_version_ | 1782131943844872192 |
---|---|
author | Sakai, S Ochiai, H Mantani, N Kogure, T Shibahara, N Terasawa, K |
author_facet | Sakai, S Ochiai, H Mantani, N Kogure, T Shibahara, N Terasawa, K |
author_sort | Sakai, S |
collection | PubMed |
description | BACKGROUND: Isoferulic acid (IFA) is a main active ingredient of the rhizoma of Cimicifuga beracleifolia, which is used frequently in Japanese traditional medicine as an anti-inflammatory drug. It has been revealed that IFA inhibits the production of macrophage inflammatory protein-2 (MIP-2), which is a murine counterpart of the chemokine family that may contribute to the pathogenesis of inflammatory diseases through the chemotactic activity for inflammatory and immune effector cells. AIM OF THE STUDY: In this study, we investigated the therapeutic effect of IFA on the progression of lethal influenza virus pneumonia in mice by comparison with that of dexamethasone (DX), a potent inhibitor for various inflammatory cytokines including MIP-2. METHODS: Mice were infected by intranasal inoculation of influenza virus under ether anesthesia. The IFA or DX was given by oral administration once daily for 4 days after infection. After infection, the survival rate and the change in body weight were daily monitored. RESULTS: IFA administration markedly improved the survival rate and body weight loss of influenza virus-infected mice in a suitable dose range (0.5 mg/day). However, DX administration did not show a beneficial effect at any dose. CONCLUSION: These data suggested that IFA is a novel tool not only for the intervention therapy, but also for the studies on the pathogenesis of influenza virus-induced pneumonia. |
format | Text |
id | pubmed-1781695 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2001 |
record_format | MEDLINE/PubMed |
spelling | pubmed-17816952007-01-25 Administration of isoferulic acid improved the survival rate of lethal influenza virus pneumonia in mice. Sakai, S Ochiai, H Mantani, N Kogure, T Shibahara, N Terasawa, K Mediators Inflamm Research Article BACKGROUND: Isoferulic acid (IFA) is a main active ingredient of the rhizoma of Cimicifuga beracleifolia, which is used frequently in Japanese traditional medicine as an anti-inflammatory drug. It has been revealed that IFA inhibits the production of macrophage inflammatory protein-2 (MIP-2), which is a murine counterpart of the chemokine family that may contribute to the pathogenesis of inflammatory diseases through the chemotactic activity for inflammatory and immune effector cells. AIM OF THE STUDY: In this study, we investigated the therapeutic effect of IFA on the progression of lethal influenza virus pneumonia in mice by comparison with that of dexamethasone (DX), a potent inhibitor for various inflammatory cytokines including MIP-2. METHODS: Mice were infected by intranasal inoculation of influenza virus under ether anesthesia. The IFA or DX was given by oral administration once daily for 4 days after infection. After infection, the survival rate and the change in body weight were daily monitored. RESULTS: IFA administration markedly improved the survival rate and body weight loss of influenza virus-infected mice in a suitable dose range (0.5 mg/day). However, DX administration did not show a beneficial effect at any dose. CONCLUSION: These data suggested that IFA is a novel tool not only for the intervention therapy, but also for the studies on the pathogenesis of influenza virus-induced pneumonia. 2001-04 /pmc/articles/PMC1781695/ /pubmed/11405556 Text en |
spellingShingle | Research Article Sakai, S Ochiai, H Mantani, N Kogure, T Shibahara, N Terasawa, K Administration of isoferulic acid improved the survival rate of lethal influenza virus pneumonia in mice. |
title | Administration of isoferulic acid improved the survival rate of lethal influenza virus pneumonia in mice. |
title_full | Administration of isoferulic acid improved the survival rate of lethal influenza virus pneumonia in mice. |
title_fullStr | Administration of isoferulic acid improved the survival rate of lethal influenza virus pneumonia in mice. |
title_full_unstemmed | Administration of isoferulic acid improved the survival rate of lethal influenza virus pneumonia in mice. |
title_short | Administration of isoferulic acid improved the survival rate of lethal influenza virus pneumonia in mice. |
title_sort | administration of isoferulic acid improved the survival rate of lethal influenza virus pneumonia in mice. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781695/ https://www.ncbi.nlm.nih.gov/pubmed/11405556 |
work_keys_str_mv | AT sakais administrationofisoferulicacidimprovedthesurvivalrateoflethalinfluenzaviruspneumoniainmice AT ochiaih administrationofisoferulicacidimprovedthesurvivalrateoflethalinfluenzaviruspneumoniainmice AT mantanin administrationofisoferulicacidimprovedthesurvivalrateoflethalinfluenzaviruspneumoniainmice AT koguret administrationofisoferulicacidimprovedthesurvivalrateoflethalinfluenzaviruspneumoniainmice AT shibaharan administrationofisoferulicacidimprovedthesurvivalrateoflethalinfluenzaviruspneumoniainmice AT terasawak administrationofisoferulicacidimprovedthesurvivalrateoflethalinfluenzaviruspneumoniainmice |